The market for Alzheimer's Disease is anticipated to expand in the coming years, driven by the development of emerging therapies.
DelveInsight has released a comprehensive report titled "Alzheimer's Disease – Market Insights, Epidemiology, and Market Forecast 2034", providing detailed analysis of Alzheimer's Disease, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key companies featured include Biogen/Eisai, BioVie, AB Science, Eli Lilly, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, and Suven Life Sciences.
Discover about the Alzheimer's Disease market report
Some of the key facts of the Alzheimer's Disease Market Report:
-
According to DelveInsight’s 2024 estimates, Alzheimer's disease affected around 16 million diagnosed individuals across the 7MM, highlighting its substantial impact on public health systems and the urgent need for innovative treatment approaches.
-
Within the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases, accounting for about 30% of the total, followed by France with 24%. DelveInsight analysts project that Alzheimer’s cases will continue to rise over the coming years.
-
In the United States, nearly 2.4 million men and 5 million women were diagnosed with Alzheimer’s in 2024, with numbers expected to increase by 2034.
-
Epidemiological analysis further shows that in the EU4 and the UK, the 75–84 age group recorded the highest prevalence of Alzheimer’s in 2024—about 2 million cases—while individuals under 65 accounted for the lowest prevalence, with around 130,000 cases.
-
Additionally, in Japan, there were an estimated 2.5 million diagnosed cases of agitation related to Alzheimer’s disease in 2024—a behavioral complication characterized by restlessness, aggression, anxiety, and irritability. This symptom significantly reduces patient quality of life and places considerable emotional and physical strain on caregivers, with case numbers expected to grow by 2034.
-
DelveInsight analysts estimated that in 2024, there were approximately 16 million diagnosed cases of Alzheimer’s disease across the 7MM. The United States alone accounted for about 44% of these cases—around 7 million—with projections indicating a continued rise by 2034. This increasing prevalence highlights the growing healthcare burden Alzheimer’s poses in the U.S.
-
In the U.S., age-specific distribution in 2024 showed that the under-65 age group had nearly 180,000 cases, the 65–74 group had approximately 1.6 million, the 75–84 age group recorded around 3 million, and the 85+ population had about 2.5 million cases.
-
Key Alzheimer's Disease companies such as Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Suven Life Sciences, and others are evaluating new drugs for Alzheimer's Disease to improve the treatment landscape.
Alzheimer's Disease Overview
Alzheimer’s disease is a chronic, progressive neurological condition that gradually impairs memory, thinking, and other cognitive functions. It is the most common cause of dementia, accounting for approximately 60–80% of all cases. While it typically develops in individuals over the age of 65, early-onset Alzheimer’s can occasionally affect people in their 40s or 50s.
Early signs often include memory loss that disrupts everyday activities, followed by confusion, difficulty with language, poor judgment, and changes in behavior. The precise cause of the disease is still unclear, but it is strongly linked to the buildup of amyloid beta plaques and tau tangles in the brain, which interferes with neural communication and triggers brain cell death. Advancing age and family history are among the primary risk factors associated with the condition.
Discover how the Alzheimer's Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Scope of the Alzheimer's Disease Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Alzheimer's Disease Companies: Biogen/Eisai, BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, KeifeRx, Eli Lilly, AriBio, Cerecin, Alzheon, Neurim Pharmaceuticals, Athira Pharma, Annovis Bio, Anavex Life Sciences, AgeneBio, Eisai, Suven Life Sciences, and others
-
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
-
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
-
Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Alzheimer's Disease Market Access and Reimbursement
To know what’s more in our Alzheimer's Disease report, visit https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Alzheimer's Disease Market Report:
-
Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer's Disease Epidemiology and Alzheimer's Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The Alzheimer's Disease market report provides insights into the current and emerging therapies.
-
The Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer's Disease market.
Got queries? Click here to know more about the Alzheimer's Disease market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Alzheimer's Disease Market Overview at a Glance
6. Alzheimer's Disease Disease Background and Overview
7. Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Alzheimer's Disease
9. Alzheimer's Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Alzheimer's Disease Emerging Therapies
12. Alzheimer's Disease Market Outlook
13. Country-Wise Alzheimer's Disease Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Alzheimer's Disease Market Outlook 2034
Related Reports:
Alzheimer's Disease Pipeline Insights, DelveInsight
"Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alzheimer's Disease market. A detailed picture of the Alzheimer's Disease pipeline landscape is provided, which includes the disease overview and Alzheimer's Disease treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
